Breaking the Barriers of Therapy Resistance: Harnessing Ferroptosis for Effective Hepatocellular Carcinoma Therapy

IF 4.2 3区 医学 Q2 ONCOLOGY
Xianmei Lv, Gaochen Lan, Lujian Zhu, Qiusheng Guo
{"title":"Breaking the Barriers of Therapy Resistance: Harnessing Ferroptosis for Effective Hepatocellular Carcinoma Therapy","authors":"Xianmei Lv, Gaochen Lan, Lujian Zhu, Qiusheng Guo","doi":"10.2147/jhc.s469449","DOIUrl":null,"url":null,"abstract":"<strong>Abstract:</strong> Ferroptosis is a type of cell death that relies on iron and is distinguished by the occurrence of lipid peroxidation and the buildup of reactive oxygen species. Ferroptosis has been demonstrated to have a significant impact on the advancement and resistance to treatment of hepatocellular carcinoma (HCC), thereby highlighting its potential as a viable therapeutic target. Ferroptosis was observed in HCC tissues in contrast to normal liver tissue. The inhibition of ferroptosis has been found to increase the viability of HCC cells and decrease their susceptibility to various anticancer therapies, including chemotherapy, radiotherapy, and immune checkpoint blockade. The administration of drugs that directly modulate ferroptosis regulators or induce excessive production of lipid-reactive oxygen species has demonstrated the potential to enhance the responsiveness of drug-resistant HCC cells to treatment. However, the precise mechanism underlying this phenomenon remains ambiguous. This review presents a comprehensive overview of the crucial role played by ferroptosis in enhancing the efficacy of treatment for hepatocellular carcinoma (HCC). The main aim of this study is to examine the feasibility of utilizing ferroptosis as a therapeutic approach to improve the efficacy of HCC treatment and overcome drug resistance. <br/><br/><strong>Keywords:</strong> ferroptosis, hepatocellular carcinoma, chemotherapy, tyrosine kinase inhibitor, immunosuppressive therapy, radiotherapy<br/>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"148 1","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatocellular Carcinoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/jhc.s469449","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Ferroptosis is a type of cell death that relies on iron and is distinguished by the occurrence of lipid peroxidation and the buildup of reactive oxygen species. Ferroptosis has been demonstrated to have a significant impact on the advancement and resistance to treatment of hepatocellular carcinoma (HCC), thereby highlighting its potential as a viable therapeutic target. Ferroptosis was observed in HCC tissues in contrast to normal liver tissue. The inhibition of ferroptosis has been found to increase the viability of HCC cells and decrease their susceptibility to various anticancer therapies, including chemotherapy, radiotherapy, and immune checkpoint blockade. The administration of drugs that directly modulate ferroptosis regulators or induce excessive production of lipid-reactive oxygen species has demonstrated the potential to enhance the responsiveness of drug-resistant HCC cells to treatment. However, the precise mechanism underlying this phenomenon remains ambiguous. This review presents a comprehensive overview of the crucial role played by ferroptosis in enhancing the efficacy of treatment for hepatocellular carcinoma (HCC). The main aim of this study is to examine the feasibility of utilizing ferroptosis as a therapeutic approach to improve the efficacy of HCC treatment and overcome drug resistance.

Keywords: ferroptosis, hepatocellular carcinoma, chemotherapy, tyrosine kinase inhibitor, immunosuppressive therapy, radiotherapy
打破抗药性障碍:利用铁蛋白沉积促进肝细胞癌的有效治疗
摘要:铁中毒是一种依赖于铁的细胞死亡类型,其特征是发生脂质过氧化和活性氧的积累。事实证明,铁蜕变对肝细胞癌(HCC)的发展和抗药性有重大影响,因此突出了其作为可行治疗靶点的潜力。与正常肝组织相比,在 HCC 组织中观察到了铁蜕变。研究发现,抑制铁突变可提高 HCC 细胞的活力,降低其对各种抗癌疗法(包括化疗、放疗和免疫检查点阻断)的敏感性。服用直接调节铁氧化调节因子或诱导过量产生脂质活性氧的药物,已证明有可能提高耐药 HCC 细胞对治疗的反应性。然而,这一现象的确切机制仍不明确。本综述全面概述了铁氧体渗透在提高肝细胞癌(HCC)疗效方面所起的关键作用。本研究的主要目的是探讨利用高铁血症作为一种治疗方法的可行性,以提高 HCC 的疗效并克服耐药性。关键词:高铁血症、肝细胞癌、化疗、酪氨酸激酶抑制剂、免疫抑制疗法、放疗
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.50
自引率
2.40%
发文量
108
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信